NeoGenomics, Inc. (FRA:NG9)
Germany · Delayed Price · Currency is EUR | Market Cap | 1.62B +84.4% |
| Revenue (ttm) | 646.98M +10.9% |
| Net Income | -86.04M |
| EPS | -0.67 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 56.87 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 11.70 |
| Previous Close | 11.21 |
| Day's Range | 11.70 - 11.70 |
| 52-Week Range | 4.20 - 11.70 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 29, 2026 |
About NeoGenomics
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and ge... [Read more]
Financial Performance
In 2025, NeoGenomics's revenue was $727.33 million, an increase of 10.11% compared to the previous year's $660.57 million. Losses were -$108.03 million, 37.2% more than in 2024.
Financial numbers in USD Financial StatementsNews
NeoGenomics appoints Starrett to its Board of Directors
NeoGenomics (NEO) announced the appointment of Carolyn Starrett to its Board of Directors. Starrett is currently the President of Starrett Advisory, an independent consulting and strategic advisory fi...
NeoGenomics Appoints Carolyn Starrett to its Board of Directors
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced the appointment of Carolyn Starrett to its Board of Directors.
NeoGenomics announces pricing of $275M convertible senior notes offering
NeoGenomics (NEO) announced the pricing of its previously announced private offering of $275M aggregate principal amount of 0.75% convertible senior notes due 2032. The notes will be senior, unsecured...
NeoGenomics Announces Pricing of Offering of $275 Million Convertible Senior Notes
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics Announces Pricing of Offering of $275 Million Convertible Senior Notes.
NeoGenomics files to sell $275M of convertible senior notes due 2032
NeoGenomics (NEO) announced that it has commenced a private offering of $275M aggregate principal amount of convertible senior notes due 2032 to persons reasonably believed to be qualified institution...
NeoGenomics Announces Proposed Offering of $275 Million Convertible Senior Notes
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics Announces Proposed Offering of $275 Million Convertible Senior Notes.
NeoGenomics Transcript: Jefferies Global Healthcare Conference 2026
Q1 saw double-digit revenue growth, driven by clinical and NGS segments, with strategic focus on proprietary product development and margin expansion. Strong ASCO engagement, new product launches, and technology upgrades support sustained growth and improved efficiency.
NeoGenomics to Present New Research at ASCO Annual Meeting 2026
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will showcase nine scientific abstracts at the 2026 ASCO Annual Meeting, May 29–June 2, 2026, in Chicago (booth #32130).
NeoGenomics Transcript: AGM 2026
The meeting covered board elections, executive compensation, equity plan amendments, and auditor ratification, with a quorum of 89.61% established. Voting results will be published in a Form 8-K, and no questions were raised during the Q&A.
Neo Performance Materials Announces C$100 Million Bought Deal Treasury Offering of Common Shares
The base shelf prospectus is accessible, and the prospectus supplement will be accessible within two business days through SEDAR+ The base shelf prospectus is accessible, and the prospectus supplement...
Neo Partners with Greenland Mines to Advance Sarfartoq Rare Earth Project
Strategic partnership positions Greenland Mines to lead exploration while Neo retains equity stake and offtake rights Strategic partnership positions Greenland Mines to lead exploration while Neo reta...
NeoGenomics to Participate in Upcoming Investor Conferences
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the Company will participate in t...
NeoGenomics price target lowered to $11 from $13 at BofA
BofA analyst Michael Ryskin lowered the firm’s price target on NeoGenomics (NEO) to $11 from $13 and keeps a Neutral rating on the shares. 1 results were “modestly positive, though…
NeoGenomics price target raised to $14 from $13 at TD Cowen
TD Cowen analyst Dan Brennan raised the firm’s price target on NeoGenomics (NEO) to $14 from $13 and keeps a Buy rating on the shares. The firm said they reported…
Leerink upgrades NeoGenomics to Outperform, raises target to $25
As previously reported, Leerink upgraded NeoGenomics (NEO) to Outperform from Market Perform with a price target of $25, up from $12. The company delivers on its one-stop shop business model…
NeoGenomics upgraded to Buy from Hold at Benchmark
Benchmark upgraded NeoGenomics (NEO) to Buy from Hold with an $11 price target after the company reported better than expected revenue and in-line earnings and said it continues to plan…
NeoGenomics upgraded to Outperform from Market Perform at Leerink
Leerink upgraded NeoGenomics (NEO) to Outperform from Market Perform with a $25 price target
NeoGenomics reports Q1 adjusted EPS 1c, consensus 0c
Reports Q1 reveneue $187M, consensus $184.48M. “The first quarter of 2026 was a truly transformational one for NeoGenomics (NEO). We again delivered double-digit revenue growth while making meaningful...
NeoGenomics raises FY26 revenue view to $797M-$803M from $793M-$801M
Consensus $796.63M. Backs FY26 adjusted EBITDA view $55M-$57M.
NeoGenomics Earnings Call Transcript: Q1 2026
Q1 2026 saw 11% revenue growth to $186.7M, led by 26% NGS growth and strong clinical demand. Guidance for 2026 was raised, with new product launches and reimbursement wins expected to drive further gains. Adjusted EBITDA rose 27% year-over-year.
NeoGenomics Earnings release: Q1 2026
NeoGenomics released its Q1 2026 earnings on April 28, 2026, summarizing the period's financial results.
NeoGenomics Slides: Q1 2026
NeoGenomics has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 28, 2026.
NeoGenomics Quarterly report: Q1 2026
NeoGenomics has published its Q1 2026 quarterly earnings report on April 28, 2026.
NeoGenomics Reports First Quarter 2026 Results
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced its first-quarter results for the period ended March 31, 2026.
NeoGenomics expands access to full oncology testing portfolio
NeoGenomics (NEO) announced that its oncology testing portfolio is now available through Epic Aura, enabling seamless access to oncologists and health systems across the United States through the Epic...